GlassScriptPhysician profile
Christopher H Wilson
NPI 1902075708
$4,369.15
in general payments reported to CMS, 2019-2025
29 companies · $564 in 2025
The $564 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $836 · 2020: $216 · 2021: $779 · 2022: $582 · 2023: $726 · 2024: $666 · 2025: $564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,910 · Education: $45.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,909.83 |
| Education | $45.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $691.80 | 2019-2024 | Gallant, Jot Dx, Assurity |
| Amgen INC. | $479.48 | 2019-2023 | Repatha |
| Novartis Pharmaceuticals Corporation | $430.84 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $360.86 | 2019-2024 | Xarelto |
| Pfizer INC. | $347.05 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $264.10 | 2019-2025 | Lifevest |
| Esperion Therapeutics, INC. | $222.41 | 2021-2025 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $149.58 | 2019-2025 | Farxiga, Lokelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.92 | 2021-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $135.22 | 2021-2023 | Verquvo |
| Kestra Medical Technology Services, INC. | $129.45 | 2023-2024 | Assure Wcd |
| Sanofi-Aventis U.S. LLC | $128.44 | 2019-2023 | |
| Novo Nordisk INC | $121.52 | 2022-2025 | Wegovy |
| E.R. Squibb & Sons, L.L.C. | $114.93 | 2021-2025 | Eliquis |
| Boston Scientific Corporation | $94.19 | 2021-2023 | Bodyguardian |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $88.25 | 2025 | Artix Mt, Inthrill Thrombectomy Catheter |
| Abiomed | $68.27 | 2024 | Impella |
| Shockwave Medical, INC | $66.27 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Medtronic, INC. | $62.21 | 2025 | Abre, Hawkone |
| Amarin Pharma, INC. | $51.72 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $50.56 | 2019-2021 | |
| Biosense Webster, INC. | $29.17 | 2023 | Na |
| Heartflow, INC. | $28.54 | 2019 | |
| Gilead Sciences, INC. | $26.47 | 2019 | |
| Alnylam Pharmaceuticals INC. | $22.40 | 2025 | Onpattro |
| Lilly USA, LLC | $21.26 | 2024 | Zepbound |
| Genzyme Corporation | $18.88 | 2023 | |
| Kiniksa Pharmaceuticals International, Plc | $15.17 | 2024 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $14.19 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.